Showing 1881-1890 of 2736 results for "".
- It's A Deal: Eirion Therapeutics, Shanghai Haohai Biological Technology Close $40M Series A Investment and Licensing Dealhttps://modernaesthetics.com/news/its-a-deal-eirion-therapeutics-inc-shanghai-haohai-biological-technology-closes-40m-series-a-investment-and-licensing-deal/2473070/Eirion Therapeutics, Inc. closed a $40 million Series A investment and licensing deal with Shanghai Haohai Biological Technology Ltd. The deal will result in a $32 million Series A Preferred Stock investment into Eirion along with exclusive licenses that will be for all of Eir
- Pre-clinical Data Suggest Soliton's RAP Technology Can Help Liver Fibrosishttps://modernaesthetics.com/news/pre-clinical-data-suggest-solitons-rap-technology-can-help-liver-fibrosis/2473066/A pre-clinical study in animals demonstrates positive results for Soliton’s RAP device as a potential treatment for liver fibrosis. Validated laboratory and histological assessments in a mouse model demonstrated that Rapid Acoustic Pulse (RAP) therapy reduced the effects of induced liver fi
- NYU Langone Health Performs World’s First Successful Face and Double Hand Transplanthttps://modernaesthetics.com/news/nyu-langone-health-performs-worlds-first-successful-face-and-double-hand-transplant/2473059/A surgical team from NYU Langone Health performed a face and double hand transplant for a 22-year-old New Jersey resident severely burned in a high-speed car crash. The surgery included transplanting both hands and t
- FDA Greenlights Galderma's Restylane Defyne for Chin Augmentationhttps://modernaesthetics.com/news/fda-greenlights-galdermas-restylane-defyne-for-chin-augmentation/2473055/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Revance: ePosters Showcase Data for DaxibotulinumtoxinA and RHA Line at Maui Dermhttps://modernaesthetics.com/news/revance-eposters-showcase-data-for-daxibotulinumtoxina-and-rha-line-at-maui-derm/2473053/Three ePosters presented at the Maui Derm for Dermatologists 2021 meeting feature data for DaxibotulinumtoxinA for Injection and the RHA® Collection of hyaluronic acid based dermal fillers, both from Revance Therapeutics. Revance repo
- Business News: Dominion Aesthetic Technologies Closes $23.7 Million Series B Financinghttps://modernaesthetics.com/news/business-news-dominion-aesthetic-technologies-closes-237-million-series-b-financing/2473052/Dominion Aesthetic Technologies, developers of EON, closed Series B financing, raising a total of $23.7 million. The series B funding will accelerate the manufacturing and commercialization of EON, an FDA-cleared 1064 nm robotic laser device used for touchless, external non-invasi
- Galderma Gives Back: New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://modernaesthetics.com/news/galderma-gives-back-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2473049/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- Managing Employees During the COVID Pandemic: Answers to Top Questionshttps://modernaesthetics.com/news/managing-employees-in-the-covid-pandemic-answers-to-top-questions/2473040/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential e
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Revance Therapeutics and Ajinomoto Bio-Pharma Services Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injectionhttps://modernaesthetics.com/news/revance-therapeutics-and-ajinomoto-bio-pharma-services-announce-manufacturing-agreement-for-supply-of-daxibotulinumtoxina-for-injection/2473035/Ajinomoto Bio-Pharma Services will serve as a supply source and provide manufacturing for Revance Therapeutics, Inc.’s DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review.